Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Paul Sekhri
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
development of oral small molecule drug candidates
treatments for metabolic and inflammatory diseases |
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:High_Point,_North_Carolina,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
vTv Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableDrugCandidate |
Azeliragon
TTP399 |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
VTVT
|
| gptkbp:website |
https://www.vtvtherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:TransTech_Pharma
|
| gptkbp:bfsLayer |
7
|